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ABSTRACT 
 
 
Three-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase competitive 
inhibitors, also known as statins, are widely used agents for lowering cholesterol and 
reducing the risk for a heart attack. Recent data suggest that statins influence bone 
metabolic activity by stimulating new bone formation both in vivo and in vitro. Bone 
resorption in periodontitis, an inflammatory disease, is orchestrated by the interaction of 
various cytokines in the inflamed tissue, produced by immune cells and also by resident 
cells such as human gingival fibroblasts (HGF) and periodontal ligament (PDL) cells. 
Three molecules, members of the tumor necrosis factor (TNF) ligand and receptor 
superfamilies, regulate the process of osteoclast formation. The first one, receptor 
activator for NF- B ligand (RANKL) is expressed on hematopoetic stromal cells and 
periosteal osteoblasts as well as on HGF and PDL cells. RANKL interacts with its 
corresponding receptor, RANK, on mononucleated osteoclast precursors and induces 
their activation to multinuclear bone resorbing osteoclasts. The effects of RANKL are 
blocked by its soluble decoy receptor, osteoprotegerin (OPG), thus inhibiting osteoclast 
differentiation, activation and survival.  RANKL and OPG are produced by many cells in 
the body including human gingival fibroblasts and PDL cells. At the moment, no data 
exist comparing the effect of statins on OPG/ RANKL production by resting and 
interleukin-1β (IL-1β)-stimulated HGF. Objective: The purpose of this project was to 
evaluate OPG and RANKL production in resting and IL-1β-stimulated HGFs, and to 
determine the effect of statins on their production. Methods: Cytotoxicity of statins was 
determined using an assay that measures the activity of a mitochondrial enzyme. 
Fibroblasts were preincubated with atorvastatin or simvastatin for 24 hours in serum-free 
medium, and then incubated without a stimulus or with IL-1β for 6 days. OPG or 
RANKL in culture supernatants was measured by specific ELISA. Data were analyzed 
using ANOVA and Scheffe’s F procedure for post hoc comparison. Results: 
Concentrations of simvastatin or atorvastatin (5 x 10-6 M to 1 x 10-11 M) had no 
significant effect on the viability of the fibroblasts, after 7 days of exposure. IL-1β (1 x 
10-8 M) increased OPG production significantly at day 1, 3 and 6, while IL-1β (1 x 10-10 
M) increased OPG production significantly only on day 6. There was a trend towards 
increasing RANKL production with IL-1β stimulation, but no statistical significance was 
reached. When they had an effect, the statins tended to increase constitutive OPG and 
RANKL production and to decrease it in the presence of IL-1β, but these findings were 
not statistically significant. Both statins significantly increased the constitutive 
RANKL/OPG ratio at multiple concentrations. At the highest concentration (5 x 10-6 M), 
atorvastatin significantly increased the IL-1β stimulated RANKL/OPG ratio. 
Conclusion: Under IL-1β stimulation and in the absence of statins, OPG production by 
HGFs was increased significantly. Simvastatin and atorvastatin differed minimally in 
their effects on OPG and RANKL production by resting and IL-1β-activated HGFs. Both 
statins increased constitutive RANKL/OPG ratios, a finding suggesting that in the 
absence of inflammation statins may influence the production of RANKL and OPG by 
HGFs to favor bone catabolism. 
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CHAPTER  1. INTRODUCTION AND LITERATURE REVIEW 
Three-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) competitive inhibitors, also 
known as statins, are widely used agents for lowering cholesterol and reducing the risk 
for a heart attack (1). They lower cholesterol by inhibiting the enzyme HMG-CoA 
reductase (HMGR), which is the rate-limiting enzyme of the mevalonate pathway of 
cholesterol synthesis (Figure 1). Inhibition of this enzyme in the liver results in decreased 
cholesterol synthesis as well as increased synthesis of low-density lipoprotein (LDL) 
receptors, resulting in an increased clearance of low-density lipoprotein from the 
bloodstream (1). The first results can be seen after one week of use and the effect is 
maximal after four to six weeks (2).  
In the 1970s the Japanese microbiologist Akira Endo first discovered natural 
products with a powerful inhibitory effect on HMGR in a fermentation broth of 
Penicillium citrinum, during his search for antimicrobial agents (3). The first product was 
named compactin (ML236B or mevastatin). In 1978, Alfred Alberts and colleagues 
discovered a new natural product in a fermentation broth of Aspergillus terreus, which 
showed good HMG-CoA reductase inhibition. They named the product mevinolin, which 
later became known as lovastatin (Figure 2) (4). The “oyster mushroom” (Figure 3), a 
culinary mushroom, naturally contains up to 2.8% lovastatin on dry weight basis (5). 
Thus, statins have been on the market for over 20 years and appear to have 
relatively good safety profiles (6). Muscle symptoms, ranging from mild myalgia to 
clinically important rhabdomyolysis, are an important side effect of these drugs and are 
the leading cause of non-compliance. However, some patients may be susceptible to 
statin myopathy because of pre-existing subclinical inherited muscular disorders, genetic 
variations in statin uptake proteins or variations in genes affecting pain perception (7). 
Statin use grew from 47% of all lipid-lowering medications in 1992 to 87% in 2002, with 
atorvastatin being the leading medication. Currently about 13 million people in the 
United States take statins to lower cholesterol levels and reduce the risk of heart disease 
(8). Statins differ in their mode of derivation as synthetic or fermentation products, 
lipophilicity, and potency. Examples of fermentation-derived statins are simvastatin, 
pravastatin and lovastatin, while atorvastatin, cerivastatin, fluvastatin, pitavastatin and 
rosuvastatin are synthetic. The essential structural components of all statins are a 
dihydroxyheptanoic acid unit and a ring system with different substituents. The statin 
pharmacophore (Figure 4) is modified hydroxyglutaric acid component, which is 
structurally similar to the endogenous substrate HMG-CoA and the mevaldyl-CoA 
transition state intermediate (9).  
The statins differ with respect to their ring structure and substituents (10). These 
differences in structure affect the pharmacological properties of the statins, such as: 
affinity for the active site of the HMGR, rates of entry into hepatic and non-hepatic 
tissues, availability in the systemic circulation for uptake into non-hepatic tissues, routes 
and modes of metabolic transformation and elimination. Statins have sometimes been  
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Figure 1. HMG-CoA reductase pathway. 
Reprinted from Wikipedia, The Free Encyclopedia. Retrieved January 15, 2010, from 
http://en.wikipedia.org/wiki/File:HMG-CoA_reductase_pathway.png (10). 
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Figure 2. Lovastatin. 
Reprinted from Wikipedia, The Free Encyclopedia. Retrieved January 
15, 2010, from http://en.wikipedia.org/wiki/Lovastatin (11). 
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Figure 3. Oyster mushroom. 
Reprinted from Wikipedia, The Free Encyclopedia. 
Retrieved March 29, 2010, from 
http://en.wikipedia.org/wiki/File:Oyster_mushroom_log.jpg (12). 
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Figure 4. The statin pharmacophore. 
Reprinted from Wikipedia, The Free Encyclopedia. Retrieved January 15, 2010, from 
http://en.wikipedia.org/wiki/Statin_development#The_statin_pharmacophore (13). 
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divided into two types according to their structure (14). Type 1 statins have substituted 
decalin-ring structure that resembles the first statin ever discovered, mevastatin. Statins 
that belong to this group are: lovastatin, simvastatin and pravastatin.  Type 2 statins are 
fully synthetic and have larger groups linked to the HMG-like moiety. One of the main 
differences between the type 1 and type 2 statins is the replacement of the butyryl group 
of type 1 statins by the fluorophenyl group of type 2 statins. This group is responsible for 
additional polar interactions that cause tighter binding to the HMGR and relatively higher 
potency of this group as compared to type 1 statins in lowering LDL. Statins that belong 
to this group are: fluvastatin, atorvastatin, cerivastatin and rosuvastatin (14). 
Mevalonate, the product of HMGR reaction, is the precursor not only of 
cholesterol, but also of many nonsteroidal isoprenoids vital for diverse cell functions. It 
appears that the inhibition of HMG-CoA reductase is responsible for numerous 
pleiotropic effects of statins such as decreasing smooth muscle cells migration and 
proliferation, stimulation of nitric oxide (NO) production, anti-apoptosis, and 
immunomodulation (14-17). Thus, in addition to their lipid-lowering effects, statins have 
shown beneficial effect in various systems: cardiovascular, immune, nervous and skeletal 
(18-21). Lately, statins have shown potential in anti-cancer therapy and as 
immunosuppressors in organ transplantation (22-24). 
Recent data suggest that statins influence bone metabolic activity by stimulating 
new bone formation both in vivo and in vitro. Mundy et al. identified statins as a potent 
activator of bone morphogenic protein-2 (BMP-2), an important stimulator of 
osteoblastic differentiation (25). In vitro studies have shown that simvastatin, mevastatin 
and atorvastatin stimulated BMP-2 transcription and also increased endogenous BMP-2 
mRNA and protein expression in human MG63 osteoblastic cells by two fold (26, 27). 
Other investigators have reported an increase in BMP-2 transcription at doses from 0.1 
µM to 5 µM for lovastatin, simvastatin, mevastatin, and atorvastatin in cultures of murine 
neonatal calvarias. Cytotoxicity resulted from higher concentrations (28). Initial in vivo 
experiments with rodents showed that when injected locally over the calvarias of normal 
mice, statins increased calvarial width by 30-50% (25). Yazawa et al. reported 
stimulation of alkaline phosphate activity of human PDL cells by simvastatin, which was 
dose-dependent (29). Maximum effect was obtained at concentration of 1 µM. In addition 
to their ability to enhance osteoblastic differentiation, statins also stimulated the 
production of OPG, which may contribute to their bone-sparing effect (30). This effect is 
amplified by the blockage of mevalonate-derivatives formation such as farnesyl-
pyrophosphate and geranyl-pyrophosphate, two agents necessary for activation of 
osteoclasts. Statins, by inhibiting the HMG-CoA reductase pathway, act to abate bone 
resorption (9). 
 
These findings in the field of bone metabolism suggest that statins could be 
considered as potential agents for treating osteoporosis and other diseases of bone loss 
such as periodontal disease (31, 32). Both diseases share common pathogenic pathways. 
Up-regulation of intereukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and interleukin-
6 (IL-6) induces osteoclastic activity and increased bone turnover rates leading to bone 
mass loss and osteoporosis (34). In addition to their osteoprotective properties, statins  
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may be able to influence the amount of tissue destruction in periodontal disease by 
interacting with the host’s immune response. It has been demonstrated that statins can 
inhibit leukocyte adhesion and extravasation in sites of inflammation. This in turn may 
result in impaired T-cell costimulation and decrease of T-cell inflammatory cytokines 
such as IL-1β, IL-6 and TNF-α as well as decreased expression on T-lymphocytes of 
molecules involved with bone metabolism (34, 35).  
 
 IL-1 exists in two isoforms, namely IL-1α and IL-1β, with similar biological 
activities (36). IL-1β is a potent multifunctional cytokine that is involved in host immune 
and inflammatory responses. The various biologic effects are due to its ability to activate 
a wide range of factors, such as matrix metalloproteinases, nitric oxide synthase, 
prostanoids and other cytokines (37). IL-1β has been established as the primary factor 
associated with the pathogenesis of periodontal disease (38-40).  It was first named 
osteoclast-activating factor because of its role in osteoclast differentiation and bone 
resorption (40). During the inflammatory response, cytokines such as IL-1β stimulate the 
periosteal osteoblasts, altering expression levels of specific protein members of the TNF 
ligand and receptor superfamilies on the osteoblast surface. 
 
Thus bone apposition and bone resorption in periodontitis are governed by the 
interaction of various stimulating and inhibiting cytokines in the inflamed tissue, 
produced by immune cells such as B- and T-lymphocytes and also by resident cells such 
as human gingival fibroblasts (HGF) and periodontal ligament (PDL) cells. Additionally, 
three molecules, members of the TNF ligand and receptor superfamilies, regulate the 
process of osteoclast formation via cell-to cell interactions (41). The first one, receptor 
activator for NF-B ligand (RANKL) is expressed on hematopoetic stromal cells and 
periosteal osteoblasts as well as on fibroblasts, and T- and B-lymphocytes. RANKL is 
expressed on osteoblasts as membrane-bound protein or cleaved into soluble form. 
RANKL interacts with its corresponding receptor RANK on mononucleated osteoclast 
precursors and induces their activation to multinuclear bone resorbing osteoclasts (42). 
The effects of RANKL are blocked by its soluble decoy receptor osteoprotegerin (OPG), 
thus inhibiting osteoclast differentiation, activation and survival (43). When OPG 
concentrations are high relative to RANKL expression, OPG binds RANKL, inhibiting 
RANK-RANKL interaction, which leads to reduced formation of osteoclasts and 
apoptosis of preexisting osteoclasts (44). This environment favors bone formation. In the 
opposite scenario, when OPG levels are low relative to RANKL levels, RANKL is 
available to bind RANK on osteoclast precursors and bone resorption is favored.  
 
Since inflammation-induced bone resorption is a hallmark of periodontal disease, 
it is expected to find increased RANKL/OPG ratio in the gingival crevicular fluid (GCF) 
of affected individuals. Indeed, elevated RANKL/OPG ratios were reported by several 
investigators. Bostanci et al. evaluated OPG and RANKL levels in healthy and 
periodontal disease subjects (45). The subjects with periodontal disease were categorized 
as: gingivitis, chronic periodontitis, generalized aggressive periodontitis and chronic 
periodontitis subjects. GCF RANKL and OPG levels were oppositely regulated in the 
periodontitis groups, but not in the gingivitis group, resulting in an elevated 
RANKL/OPG ratio. This ratio was similar in all three periodontitis groups and may 
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therefore predict disease occurrence. Therefore, the inhibition of RANKL by OPG may 
represent an important therapeutic strategy for the prevention and treatment of 
periodontal disease. 
 
This assumption was used by Jin et al. when creating an experimental 
periodontitis model in rats and evaluating the effect of RANKL inhibition by OPG on 
bone loss (46). A total of 32 rats were administered human OPG-Fc fusion protein (10 
mg/kg) or vehicle by subcutaneous delivery twice weekly for 6 weeks. Biopsies were 
harvested after 3 and 6 weeks, and mandibles were evaluated by microcomputed 
tomography (microCT) and histology. Significant preservation of alveolar bone volume 
was observed among OPG-Fc-treated animals compared to the controls at weeks 3 and 6. 
Descriptive histology revealed that OPG-Fc significantly suppressed osteoclast surface 
area at the alveolar crest. The results support the hypothesis that RANKL inhibition by 
OPG may represent an important therapeutic strategy for the prevention of progressive 
alveolar bone loss.  
 
RANKL and OPG are produced by many cells in the body including HGF and 
PDL cells (47, 48). Some studies report an increase in OPG production by HGF when 
stimulated by lipopolysaccharide (LPS) from Aggregatibacter actinomycetemcomitans 
(A.a.) and Porphyromonas gingivalis (P.g.), which appears to inhibit monocyte 
differentiation into osteoclasts (48, 49).  Other studies report induced RANKL and 
reduced OPG mRNA expression by HGF resulting in an increased RANKL/OPG 
expression ratio by P.g. (50). Thus, the resident cells may play a major role in 
RANK/RANKL/OPG balance at connective tissue/bone interface in health and in 
diseased states. Modulation of their secretory activity may be useful in achieving the 
primary goal for periodontal therapy, namely prevention of further soft and hard tissue 
destruction and regeneration of lost structures. 
 
While a limited number of studies have focused on OPG/RANKL production by 
HGF, no studies have systematically evaluated the effect of IL-1β or statins on HGF 
production of both OPG and RANKL. Therefore the purpose of this study is to evaluate 
OPG and RANKL production in resting and IL-1β-activated HGF in the presence and 
absence of statins.  
 
 
Purpose of Study 
 
The overall purpose of this project was to examine the effects of two different 
statins, simvastatin and atorvastatin, on RANKL and OPG production by cultured human 
gingival fibroblasts. 
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Hypothesis 
 
Based on the differences in the mode of derivation and potency, the hypothesis 
tested was that simvastatin and atorvastatin differ in their effect on OPG and RANKL 
production in resting and IL-1β-activated human gingival fibroblasts. 
 
 
Specific Aims 
 
 Specific Aim 1: To quantify constitutive OPG and RANKL production by human 
gingival fibroblasts. 
 Specific Aim 2: To quantify OPG and RANKL production by human gingival 
fibroblasts following IL-1β stimulation. 
 Specific Aim 3:  To determine the effect of atorvastatin and simvastatin on OPG 
and RANKL production in resting and IL-1β-stimulated HGF. 
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CHAPTER  2. MATERIALS AND METHODS 
 
 
Human Gingival Fibroblasts  
 
A normal human gingival fibroblast cell line, previously established and available 
for the study, was used in this work. The cell line was established from gingival explants 
using standard techniques. The gingival explants were minced using a scalpel and then 
washed with Dulbecco’s Modified Eagle Medium (DMEM; Gibco; Grant Island, NY) 
supplemented with 10% (v/v) newborn calf serum (NCS; Gibco) and 100 μg/ml 
gentamicin (Sigma-Aldrich Co; St Louis, MO) (complete medium), supplemented with 
2.5 μg/ml amphotericin B (Sigma-Aldrich Co; St Louis, MO), 100 U/ml penicillin 
(Sigma-Aldrich Co; St Louis, MO) and 100 μg/ml streptomycin. The tissue pieces were 
placed in 25 cm² flasks, allowed to adhere, and then incubated in complete medium at 
37°C in a humidified atmosphere of 5% CO2 in air until outgrowth of fibroblasts 
occurred (within two weeks). At the point of confluency in the 25 cm² flasks, the cells 
were removed from the flasks by a brief (5 min) treatment with trypsin (0.25%; Gibco), 
transferred to 75 cm² flasks, and routinely cultured in complete medium. 
 
 
Statins and IL-1β 
  
Atorvastatin was provided by Pfizer (Groton, CT) at no cost through a material 
transfer agreement. Simvastatin was purchased from Sigma–Aldrich.  Both drugs are 
soluble in dimethyl sulfoxide (DMSO). Simvastatin is a synthetic derivative of a 
fermentation product of Aspergillus terreus. It is the only statin available in generic form. 
Atorvastatin is a completely synthetic product and has been found to be more potent 
compared to other statins at equal concentration and incubation time. Human 
recombinant IL-1β was purchased from R&D Systems, (Minneapolis, MN). 
 
 
Determination of Cytotoxic Effect of Statins on Human Gingival Fibroblasts 
 
  In order to determine non-cytotoxic doses of the statins for experimental use, the 
effects of the drugs on cell viability were measured by determining their effects on the 
ability of the cells to cleave the tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide) (MTT) to a formazan dye, using a kit from Boehringer 
Mannheim Corp. (Indianapolis, IN). Cells (2.5 x 104) were exposed to DMEM containing 
100 g/ml gentamicin (DMEM-gent) in the presence or absence of simvastastin or 
atorvastatin (5 x 10-6 M to 1 x 10-11 M) (final DMSO concentration = 0.1%).  After 
exposure time of 7 days, MTT was added to the cells. Purple formazan crystals produced 
from the MTT by metabolically active cells were solubilized and absorbance read at 540 
nm. Results were expressed as percent of control (A540nm in cells exposed to DMEM-
gent-0.1% DMSO only). 
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Determination of Constitutive and IL-1β-stimulated Production of RANKL and 
OPG 
 
To obtain conditioned media, the cells were seeded at 3 x105 in 6-well plates in 
complete medium and cultured overnight at 37C.  This medium was removed and the 
wells were washed with PBS. DMEM-gent with or without IL-1β was added. 
Experimental conditions varied by incubation time, and concentration of IL-1β. 
Production of RANKL and OPG was measured in fibroblast-conditioned media using the 
Human DuoSet OPG ELISA Development System (R&D Systems), and a RANKL 
ELISA (Pepro Tech, Inc.; Rocky Hill, NJ).  The media were harvested at specific time 
points (i.e. 1-6 d), and samples were assayed using specific ELISA to measure the levels 
of OPG or RANKL, per the manufacturer’s instructions.  Absorbance values were read 
using a microtiter plate spectrophotometer, and the results were expressed as the 
concentration of OPG or RANKL (pg/ml). 
 
 
Determination of the Effects of Statins on Constitutive and IL-1β-stimulated 
Production of RANKL and OPG 
 
The initial step of this experiment was carried out as described in the preceding 
section. After the wells were washed with PBS, DMEM-gent (1.5 ml/well) with or 
without statins (5 x 10-6 M to 1 x 10-11 M) (final DMSO concentration = 0.1%) was 
added. After 24 hours IL-1β (1 x 10-10 M) was added. Previous work from this laboratory 
established the lack of toxicity of 1x 10-10 M IL-1β, which was used as a stimulus in this 
last part of the study. The media were harvested at day six. Samples were assayed using 
the specific ELISA to measure the levels of OPG or RANKL, per the manufacturer’s 
instructions. Absorbance values were read using a microtiter plate spectrophotometer, 
and the results were expressed as the amount of OPG or RANKL (pg/ml). These results 
were converted to percent of control (amount made by cells exposed to DMEM-gent-
DMSO only, set at 100%). 
 
 
Statistical Analysis 
 
All experiments were performed multiple times with triplicate samples. The data 
were expressed as mean ± standard deviation and were analyzed using a one-way 
analysis of variance (ANOVA) and Scheffe’s F procedure for post hoc comparisons, 
using StatView® software. 
 
 
 
 
 
 
 
 
  
12 
 
CHAPTER 3. RESULTS 
 
 
Cytotoxic Effect of Statins on Human Gingival Fibroblasts 
 
Cytotoxic effects of simvastatin and atorvastatin were determined using the MTT 
assay, which measures the ability of the fibroblasts to cleave the tetrazolium salt MTT to 
a formazan dye. The results were expressed as percent of control (A540nm in cells exposed 
to DMEM-gent-0.1% DMSO only). Concentrations of simvastatin or atorvastatin of 5 x 
10-6 M to 1 x 10-11 M had no significant effect on the viability of the fibroblasts, after 7 
days of exposure (Figure 5). 
 
 
Effect of IL-1β on Constitutive OPG Production 
 
Previous work in this laboratory established lack of toxicity of 1 x 10-10 M IL-1β 
on the cell line used. Incubation times ranged from one to six days.  Statistically 
significant increase (p<0.0001) was seen on day 1 between control and 1 x 10-8 M IL-1β 
(Figure 6). The increase (p=0.005) persisted on day 3 at the same concentration. On day 
6, there was statistically significant difference for two concentrations of IL-1β: 1 x 10-8 M 
and 1 x 10-10 M (p=0.001) (Figure 6). Constitutive OPG levels produced by HGF were in 
the ng/ml range, and following IL-1β stimulation, the levels were increased by as much 
as 10- fold. 
 
The levels of OPG (and RANKL) for the rest of the experiments were first 
expressed as ng/ml or pg/ml in the cell supernatants and then converted to percent of the 
control (amount produced by cells not exposed to the drug), set at 100 percent.  
 
 
Effect of IL-1β on Constitutive RANKL Production 
 
Identical incubation times as described in previous experiments for OPG were 
used for evaluating the effect of IL-1β on constitutive RANKL production. Constitutive 
RANKL levels produced by HGF were in the pg/ml range. There was a trend towards 
increasing RANKL production with IL-1β stimulation, especially at days 3 and 6. 
Following IL-1β stimulation, the levels of RANKL were increased 1-2 fold. None of the 
changes were statistically significant by Scheffe’s test (Figure 7). 
 
 
Effect of Statins on Constitutive RANKL Production  
 
Both drugs in concentration range of 5 x 10-6 M to 1 x 10-11 M increased 
constitutive production of RANKL (Figures 8 and 9). Atorvastatin had a more robust 
effect on constitutive RANKL production compared to simvastatin especially at 1 x 10-10 
M and 1 x 10-11 M. No increase reached statistical significance. 
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Figure 5. Cytotoxic effect of statins on human gingival fibroblasts. 
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Figure 6. Effect of IL-1β on constitutive OPG production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 7. Effect of IL-1β on constitutive RANKL production. 
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Figure 8. Effect of simvastatin on constitutive RANKL production. 
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Figure 9. Effect of atorvastatin on constitutive RANKL production. 
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Effect of Statins on IL-1β-stimulated RANKL Production 
 
All concentrations of simvastatin (except 5 x 10-6 M) decreased the IL-1β-
stimulated production of RANKL. Maximum decrease was achieved for 1 x 10-8 M of 
simvastatin. All concentrations of atorvastatin (except 1 x 10-7 M and 1 x 10-8 M) 
increased the IL-1β-stimulated production of RANKL (Figures 10 and 11). Maximum 
increase in IL-1β stimulated RANKL was noticed again for 1 x 10-10 M and 1 x 10-11 M, 
while maximum decrease was achieved at 1 x 10-7 M of atorvastatin. None of the effects 
reached statistical significance. 
 
 
Effect of Statins on Constitutive OPG Production  
 
Simvastatin had a minimal effect on constitutive OPG production (Figure 12). 
Atorvastatin showed a trend towards increasing the constitutive production of OPG 
(Figure 13). The greatest increase was seen at 1 x 10-11 M. No statistical significance was 
detected for either drug for any concentration. 
 
 
Effect of Statins on IL-1β-stimulated OPG Production  
  
Most simvastatin concentrations had no effect on IL-1β stimulated production of 
OPG (Figure 14). A small decrease was noted at 1 x 10-6 M concentration. Atorvastatin 
showed a trend towards decreasing IL-1β-stimulated OPG production (Figure 15). 
However, decreases were noted at 1 x 10-6 M and 5 x 10-6 M, while the greatest increase 
in IL-1β-stimulated OPG production was seen at 1 x 10-11 M. Neither drug at any 
concentration produced a statistically significant change. 
 
 
Effect of Statins on Constitutive RANKL/OPG Ratios 
 
Both drugs in the concentrations tested increased the constitutive RANKL/OPG 
ratios (Figure 16). Statistical significance was detected by the Scheffe’s test for several 
concentrations of atorvastatin (1 x 10-10 M, 1 x 10-6 M and 5 x 10-6 M) and simvastatin  
(1 x 10-11 M, 1 x 10-8 M, 1 x 10-7 M, 1 x 10-6 M and 5 x 10-6 M). Atorvastatin at 1 x 10-10 
M (p<0.0001) produced 2.7 fold increase. Simvastatin at concentrations 1 x 10-11 M 
(p<0.04) and 1 x 10-8 M (p=0.01) produced the smallest increase. 
 
 
Effect of Statins on IL-1β-stimulated RANKL/OPG Ratios 
 
Most concentrations of simvastatin decreased IL-1β-stimulated RANKL/OPG 
ratios. The decrease was greatest at 1 x 10-7 M and 1 x 10-8 M, but did not reach statistical 
significance (Figure 17). Most concentrations of atorvastatin increased the ratio. There 
was a statistically significant increase (p=0.002) in the IL-1β-stimulated RANKL/OPG 
ratio at 5 x 10-6 M atorvastatin.  
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Figure 10. Effect of simvastatin on IL-1β-stimulated RANKL production. 
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Figure 11. Effect of atorvastatin on IL-1β-stimulated RANKL production. 
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Figure 12. Effect of simvastatin on constitutive OPG production. 
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Figure 13. Effect of atorvastatin on constitutive OPG production. 
 
  
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Effect of simvastatin on IL-1β-stimulated OPG production. 
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Figure 15. Effect of atorvastatin on IL-1β-stimulated OPG production. 
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Figure 16.  Effect of simvastatin or atorvastatin on constitutive RANKL/OPG ratios. 
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Figure 17. Effect of simvastatin or atorvastatin on IL-1β-stimulated RANKL/OPG ratios. 
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CHAPTER 4. DISCUSSION 
 
 
This study examined the effect of simvastatin and atorvastatin on constitutive and 
IL-1β-stimulated production of OPG and RANKL by human gingival fibroblasts. 
Gingival fibroblasts, periodontal ligament fibroblasts, and osteoblasts are the three types 
of fibroblastic cells of mesenchymal origin in human periodontal tissue (47). Gingival 
fibroblasts make up 65% of the cell population in gingiva, and appear to be active 
participants in soft and hard tissue remodeling (51). As discussed in Chapter I, human 
gingival fibroblasts and periodontal ligament fibroblasts can produce RANKL and OPG. 
Therefore in addition to osteoblasts, it is now believed that fibroblasts are involved in the 
regulation of alveolar bone metabolism (47-50, 52). It is unknown however whether 
statins have an effect on OPG and RANKL production by human gingival fibroblasts. 
Therefore the purpose of this study was to evaluate the constitutive and IL-1β-stimulated 
production of OPG and RANKL by human gingival fibroblasts in the presence or 
absence of statins. 
 
Simvastatin and atorvastatin were used in this study. They are two of the most 
frequently prescribed statins, either as monotherapy or in combination with other lipid 
lowering agents. Simvastatin is a synthetic derivate of a fermentation product of 
Aspergillus terreus. It is the only statin available in generic form. It also the most often 
used statin in research. Several investigators reported simvastatin-induced osteoblastic 
differentiation through its bone morphogenic protein-2 promoting effect, which resulted 
in greater new bone formation and improved fracture healing (53-57). Simvastatin has 
been used in the treatment of periodontal and peri-implant bone defects as well in socket 
preservation (58-60). One interesting fact about simvastatin metabolism is that the parent 
drug is without intrinsic activity. However, it is readily metabolized to simvastatin acid 
by nonenzymatic hydrolysis as well as by nonspecific esterases in the liver and other 
tissues. Simvastatin, but not simvastatin acid undergoes microsomal metabolism. Several 
metabolites resulting from microsomal oxidation are effective inhibitors of 3-hydroxy-3-
methylglutaryl-CoA reductase and may contribute to the cholesterol lowering effect of 
simvastatin (61).  
 
Atorvastatin is a completely synthetic product and has been found to be more 
potent compared to other statins at equal concentration and incubation time (28).  
Atorvastatin produces larger reductions of cholesterol and triglycerides compared with 
other drugs in this class (62). It has also been shown to reduce the levels of small, dense 
LDL (63). It is still awaiting its generic launch. It is metabolized solely by CYP3A4 (62). 
Liver metabolism produces two active hydroxyl  metabolites, ortho-hydroxy-atorvastatin 
(o-OH-atorvastatin) and para-hydroxy-atorvastatin (p-OH-atorvastatin), and three 
corresponding inactive lactone metabolites (64). The active metabolites are equipotent to 
the parent drug in vitro. Elimination of the drug is mainly through the bile; renal 
excretion of radiolabelled drug and metabolites in urine is negligible (65). In contrast to 
other statins, dosage adjustment to avoid accumulation in patients with renal impairment 
is not necessary (66). 
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The effect of statins on OPG and RANKL production has been investigated in 
several cell culture systems and the results are controversial.  Kaji et al. reported an 
increase in OPG and decrease in RANKL mRNA in mouse bone cell cultures when the 
cells were treated with mevastatin and simvastatin (67). The authors suggested that the 
modulation of OPG/RANKL ratio may be responsible for reduced osteoclast formation. 
 
Similar results were reported by Viereck et al. when human osteoblasts were 
treated with atorvastatin (30). There was a time-dependent stimulatory effect of 
atorvastatin on OPG mRNA levels after 24 h and on OPG protein secretion after 48-72 h. 
The data suggested that atorvastatin enhanced osteoblastic differentiation and production 
of OPG, which may be contributory to the bone-sparing effects of statins. However, 
statins had an opposite effect on OPG production by endothelial and smooth muscle cells 
in vitro (68). The authors demonstrated that statins reduced TNF-α-induced OPG 
production in cultured human endothelial cells and smooth muscle cells. In addition, 
atorvastatin downregulated IL-1α-induced OPG production in endothelial cells. The 
effect of statins on TNF-α-induced OPG production was reversed by mevalonate and 
geranyl–geranyl pyrophosphate at the level of protein production and at the level of 
mRNA expression, suggesting that it was brought about by inhibition of the mevalonic 
acid pathway and protein prenylation. 
 
Nellemann et al. examined the effect of simvastatin on OPG and adhesion 
molecules in type 2 diabetic patients with microalbuminuria (69). Since elevated OPG 
levels are associated with subclinical atherosclerosis in both type 1 and type 2 diabetes, 
these findings may reflect a simvastatin-calcification reduction (70, 71).  Thus the effects 
of statins on RANKL and OPG production appear to be cell-culture specific.  
 
In the present study, the concentrations of simvastatin and atorvastatin ranged 
from 5 x 10-6 to 1 x 10-11 M. This range is inclusive of the range of concentrations of 
these and other statins studied by others (25, 72, 73). Neither drug at any concentration 
tested, at any time point, was toxic to the fibroblasts (Figure 5). These findings confirm 
previously reported lack of toxicity of statins in concentration less than 5 x 10-6 M (28, 
74). The lack of toxicity of IL-1β in the concentration tested (1 x 10-10 M) was based on 
results from previous studies in this lab (75). Evaluation of the effect of IL-1β on 
constitutive OPG production showed statistically significant difference on day 1 between 
control and 1 x 10-8 M, p<0.0001 (Figure 6). It continued on day 3 for the same 
concentration (p<0.005). On day 6, there was statistically significant difference for two 
concentrations of IL-1β (1 x 10-8 M and 1 x 10-10 M, p=0.001 (Figure 6). Thus under IL-
1β stimulation, HGFs increase their OPG production, acting to prevent osteoclast 
formation and bone resorption. Similar findings were reported by Nagasawa et al. when 
human gingival fibroblasts were stimulated by LPS (48). The culture supernatant of LPS-
stimulated gingival fibroblasts significantly reduced the number of TNF-receptor 
associated protein (TRAP) positive cells generated by culturing monocytes with RANKL 
and macrophage colony-stimulating factor (M-CSF). The results suggested that LPS-
stimulated HGFs inhibit monocyte differentiation into osteoclasts through the production 
of OPG. Similarly Sakata et al. reported increased OPG level when human periodontal 
ligament cells under IL-1β stimulation (76). These effects of IL-1β on OPG production 
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are applicable to cell lines not present in the periodontium. When IL-1β was used as 
stimulus in chondrocyte cell culture, OPG and RANKL expression increased with IL-1β 
whereas M-CSF expression decreased. The results suggested that IL-1β suppresses the 
formation of osteoclast-like cells via increased OPG production and decreased M-CSF 
production in chondrocytes, thus decreasing cartilage turnover (77). In this study, a trend 
towards increasing RANKL production with IL-1β stimulation was seen, especially at 
days 3 and 6. No statistical significance was detected. Similar results were reported by 
Nukaga et al. when evaluating the effect of IL-1β on PDL cells (78). The authors 
concluded that IL-1β stimulated the expression of RANKL at messenger RNA (mRNA) 
and protein levels and the effect was partially mediated by endogenous PGE2.    
 
The effects of both drugs on constitutive or IL-1β-stimulated production of OPG 
and RANKL did not reach statistical significance at any concentrations. Both drugs 
increased the constitutive RANKL/OPG ratio, an effect favoring bone resorption. 
Statistical significance was detected for several of the concentrations tested. Simvastatin 
decreased slightly IL-1β-stimulated RANKL/OPG ratio (except for the highest 
concentrations of 5 x 10-6 M and 1 x 10-6 M). Atorvastatin increased IL-1β-stimulated 
RANKL/OPG ratio (except for 1 x 10-7 M and 1 x 10-8 M). Only the highest 
concentration of atorvastatin (5 x 10-6 M) produced statistically significant effect.  
 
Thus the statins tested in this study differ minimally in their effect on 
RANKL/OPG ratios. The constitutive increase of RANKL/OPG ratio by atorvastatin and 
simvastatin could be a clinical reflection of the findings reported by Saxlin et al. (34). 
The study investigated the association between statin medication (simvastatin, 
atorvastatin or other) and periodontal infection in an adult non-diabetic, non-rheumatic 
population. The main outcome variable was the presence of periodontal infection 
measured in two ways: number of teeth with deepened periodontal pockets (4 mm or 
more) and number of teeth with deep periodontal pockets (6 mm or more). Bleeding on 
probing was also used as an outcome variable. Statin medication was weakly negatively 
associated with the presence and extent of periodontal infection. In stratified analyses, 
this beneficial effect was seen only in subjects with dental plaque or gingival bleeding. 
Among subjects with no gingival bleeding and to a lesser extent among subjects with no 
plaque, statin medication was associated with an increased likelihood of having teeth 
with deepened periodontal pockets. The results of the study suggested that statins have an 
effect on the periodontium that is dependent on the inflammatory condition of the 
periodontium. 
 
Since the absence of bleeding on probing has a high negative predictive value for 
disease progression and deepened periodontal pockets are often associated with bone 
loss, the results reported by Saxlin et al. may be correlated to the increase in 
RANKL/OPG ratio by atorvastatin and simvastatin in the absence of IL-1β stimulation, a 
surrogate of inflammation (79). The finding that both statins increased constitutive 
RANKL/OPG ratios, suggests that in non-diseased state statins may influence the 
production of RANKL and OPG by HGFs to favor bone catabolism and confirms the 
suggestion by Saxlin et al. that the effect of statin medication may be dependent on the 
inflammatory condition of the periodontium. 
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The results from this study suggest that in non-stimulated cells statins may have a 
negative effect on RANKL/OPG balance by increasing the ratio and favoring bone 
resorption. Outcomes from other investigations are more favorable in terms of positive 
effect of statins on periodontal health. Therefore statins should not be dismissed as a 
potential therapeutic agent to prevent or recover bone loss in periodontal disease. Lindy 
et al. reported that statin use was associated with fewer numbers of pathologically 
deepened periodontal pockets compared with subjects not taking statin medication among 
chronic periodontitis patients (80).  Pradeep et al. investigated the effectiveness of 1.2 mg 
simvastatin in a biodegradable controlled-release gel as an adjunct to scaling and root 
planing (SRP) in the treatment of chronic periodontitis (81). Clinical parameters were 
recorded at baseline before SRP and 1, 2, 4 and 6 months; they included modified sulcus 
bleeding index (mSBI), probing pocket depth (PPD), and relative attachment level 
(RAL). At the baseline and after 6 months, radiological assessment of intrabony defect 
(IBD) fill was done using computer-aided software. There was greater reduction in 
gingival index and PPD, and more RAL gain with significant IBD fill at sites treated with 
SRP plus locally delivered simvastatin in chronic periodontitis patients. 
 
The results of this study are only applicable to the gingival fibroblast cell line 
used and should not be used to draw general conclusions about the gingival fibroblast 
population as an entity present in the gingiva. It should be emphasized, that the results of 
the study support the conclusion from previous investigators regarding the 
osteoprotective properties of gingival fibroblasts based on their elevated constitutive 
production of OPG (ng range) vs. RANKL (pg range) and confirm the role of gingival 
fibroblasts in bone metabolism. Under IL-1β stimulation, OPG production was increased 
by as much as 10-fold compared to control. Clinically, under inflammatory conditions 
such as periodontitis-induced bone damage, the increased production of OPG by gingival 
fibroblasts may act to abate bone resorption by decreasing the RANKL/OPG ratio. 
Further investigations are needed to verify the validity of our findings and determine the 
effects of statins on OPG and RANKL production by human gingival fibroblasts in the 
presence or absence of inflammatory mediators such as IL-1β. 
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